

David C Linch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7175626/publications.pdf>

Version: 2024-02-01

22
papers

4,764
citations

567281
15
h-index

713466
21
g-index

23
all docs

23
docs citations

23
times ranked

5165
citing authors

#	ARTICLE	IF	CITATIONS
1	The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. <i>Blood</i> , 2001, 98, 1752-1759.	1.4	1,392
2	The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. <i>Blood</i> , 2008, 111, 2776-2784.	1.4	666
3	Assessment of Minimal Residual Disease in Standard-Risk AML. <i>New England Journal of Medicine</i> , 2016, 374, 422-433.	27.0	662
4	Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. <i>Lancet</i> , The, 2013, 381, 1817-1826.	13.7	450
5	Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. <i>Blood</i> , 2002, 100, 2393-2398.	1.4	287
6	Acute myeloid leukaemia. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16010.	30.5	277
7	Prognostic Significance of <i>CEBPA</i> Mutations in a Large Cohort of Younger Adult Patients With Acute Myeloid Leukemia: Impact of Double <i>CEBPA</i> Mutations and the Interaction With <i>FLT3</i> and <i>NPM1</i> Mutations. <i>Journal of Clinical Oncology</i> , 2010, 28, 2739-2747.	1.6	270
8	The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. <i>Blood</i> , 2011, 118, 409-412.	1.4	233
9	Impact of FLT3ITD mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia. <i>Blood</i> , 2014, 124, 273-276.	1.4	108
10	Investigation of early T cell activation: Analysis of the effect of specific antigen, interleukin 2 and monoclonal antibodies on intracellular free calcium concentration. <i>European Journal of Immunology</i> , 1985, 15, 7-11.	2.9	91
11	Signal Transduction in Human T Lymphocytes. <i>Immunological Reviews</i> , 1987, 95, 137-159.	6.0	88
12	Simpson's Paradox and the Impact of Different <i>DNMT3A</i> Mutations on Outcome in Younger Adults With Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2015, 33, 2072-2083.	1.6	82
13	Burkitt lymphoma in adults. <i>British Journal of Haematology</i> , 2012, 156, 693-703.	2.5	55
14	Unusual T cell proliferations and neutropenia in rheumatoid arthritis: comparison with classical Felty's syndrome. <i>Scandinavian Journal of Haematology</i> , 1984, 33, 342-350.	0.0	37
15	Rituximab in combination with CODOX/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%. <i>British Journal of Haematology</i> , 2011, 152, 175-181.	2.5	29
16	Analysis of the clinical impact of <i>NPM1</i> mutant allele burden in a large cohort of younger adult patients with acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 188, 852-859.	2.5	13
17	Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute CHOP 14 versus 21 phase 3 trial. <i>British Journal of Haematology</i> , 2021, 192, 1015-1019.	2.5	8
18	Favourable outcomes for high-risk Burkitt lymphoma patients (IPI 3-5) treated with rituximab plus CODOX/IVAC: Results of a phase 2 UK NCRI trial. <i>EJHaem</i> , 2020, 1, 133-141.	1.0	5

#	ARTICLE	IF	CITATIONS
19	The clinical impact of mutant <i>DNMT3A</i> R882 variant allele frequency in acute myeloid leukaemia. British Journal of Haematology, 2020, 189, e81-e86.	2.5	5
20	Therapy for isocitrate dehydrogenase 2 (<i>IDH2</i>) ^{R172} -mutant acute myeloid leukaemia. British Journal of Haematology, 2022, 196, 1348-1352.	2.5	3
21	Developments over the last 60 years in diffuse large B-cell lymphomas. British Journal of Haematology, 2020, 191, 552-557.	2.5	2
22	Additional impact of mutational genotype on prognostic determination in resistant and relapsed acute myeloid leukaemia. Leukemia Research, 2021, 108, 106553.	0.8	0